Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TATE and KN046 for Advanced Colorectal Cancer with Liver Metastasis
NCT06834399Phase 2Terminated
- Sponsor
- Raygene
- Start
- Apr 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erfonrilimab and tirapazamine in colorectal cancer (CRC), sponsored by Raygene. Primary endpoints: Objective Response Rate at 24 months and Overall Survival at 24 months. Started Apr 2023; status: terminated.
02
Drugs
erfonrilimabtirapazamine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06834399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06834399.